ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors"

1,127 views
July 6, 2023
Vivek Subbiah, MD, now Chief of Early-Phase Drug Development for Sarah Cannon Research Institute (SCRI), ...
read more ↘
0 Comments
Login to view comments. Click here to Login